tirzepatide release date Tirzepatide) is the most effective obesity drug we have to date, and it seems to be thanks to its “dual effect”: it acts as a GLP-1 receptor agonist but also as another Who Makes Retatrutide? Company Behind

Food and Drug Administration (FDA) approved Sermorelin in 1990 for the treatment of growth hormone deficiency in children

In 2023, the Saudi Food and Drug Authority (SFDA) implemented the Guideline for Registration of Human Medicinal Products, 2023 issued by the Saudi Food and Drug Authority, which introduced streamlined procedures for the approval of GLP-1 agonists

"It is a word that resonates with people

For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025

If berberine slows them down, levels of other drugs can rise, sometimes to unsafe levels

2022 folgte die Zulassung von Semaglutid (Wegovy) fr die gleichen Indikationen